Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 18/20 | 0.67 |
| ▸ | PDE7B | Q9NP56 | 3/20 | 0.60 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5234518 | 0.92 | PDE7A (0.67) | PDE7APDE7BPDE4DPDE5A | |
| SCHEMBL5230536 | 0.92 | PDE7A (0.79) | PDE7APDE7BPDE4D | |
| SCHEMBL27512336 | 0.91 | PDE7A (0.61) | PDE7APDE7BPDE4DPDE5A | |
| SCHEMBL5233392 | 0.91 | PDE7A (0.67) | PDE7APDE7BPDE4DPDE5A | |
| SCHEMBL5228275 | 0.91 | PDE7A (0.61) | PDE7APDE7BPDE4DPDE5A | |
| SCHEMBL5229877 | 0.91 | PDE7A (0.61) | PDE7APDE7BPDE4DPDE5A | |
| SCHEMBL5233104 | 0.91 | PDE7A (0.58) | PDE7APDE7BPDE4DPDE5AHDAC1 | |
| SCHEMBL5231454 | 0.91 | PDE7A (0.60) | PDE7APDE7BPDE4DPDE5AHDAC1 | |
| SCHEMBL5234103 | 0.90 | PDE7A (0.59) | PDE7APDE7BPDE4DPDE5AHDAC1 | |
| SCHEMBL5230073 | 0.90 | PDE7A (0.59) | PDE7APDE7BPDE4DPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1454897-B1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7-INHIBITORY ACTIVITY | ASUBIO PHARMA CO LTD (JP) | 2007-10-10 | — | — | EP | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268128-B2 | 1,3,5-trisubstituted-5-phenyl and 5-pyridyl pyrazolopyrimidinone derivatives having PDE7 inhibiting action | AUSBIO PHARMA CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | OMEROS CORPORATION | 2005-07-07 | — | — | US | disclosed |
| EP-1454897-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES HAVING PDE7−INHIBITORY ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148604-A1 | Pyrazolopyrimidinone derivatives having PDE7 inhibiting action | PDE7B, PDE3B, PDE3A | PDE7A 4/4885PDE7B 1/4885PDE4D 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.